BioPharma Dive October 21, 2024
Sponsored content By Syngene
The biopharmaceutical industry has been a hotbed of innovation in recent years, with an increasing number of novel recombinant protein therapeutics receiving the U.S. Food and Drug Administration’s (FDA) green light. However, these therapies are often very expensive, highlighting the ever-growing need for improved efficiency and productivity. One of the key levers in enhancing productivity is the cell line and the upstream processing which drive the quantity of product made while all subsequent downstream steps enhance the quality of the product.
Despite the remarkable advancements fuelled by the development of recombinant technologies, innovative media formulations and precise process control strategies, hurdles persist, particularly for startups and small biopharma teams. Equipment availability and varying quality of...
Today's Sponsors
Today's Sponsor